Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 465

Similar articles for PubMed (Select 17328073)

1.

The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA.

Arthritis Rheum. 2007 Mar;56(3):965-71.

2.

Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.

Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA.

Arthritis Rheum. 2007 Nov;56(11):3793-804.

3.

Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages.

Shimizu M, Yachie A.

Cytokine. 2012 Oct;60(1):226-32. doi: 10.1016/j.cyto.2012.05.003. Epub 2012 Jun 8.

PMID:
22682876
4.

Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.

Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P.

Am J Kidney Dis. 2006 Dec;48(6):916-25.

PMID:
17162146
5.

Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.

Baeten D, Møller HJ, Delanghe J, Veys EM, Moestrup SK, De Keyser F.

Arthritis Rheum. 2004 May;50(5):1611-23.

6.

Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.

Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A.

Int J Rheum Dis. 2014 Mar;17(3):261-7. doi: 10.1111/1756-185X.12196. Epub 2014 Jan 13.

PMID:
24417800
7.

Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.

Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G.

Crit Care Med. 2006 Oct;34(10):2561-6.

PMID:
16915112
8.

Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome.

Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A.

Eur J Haematol. 2005 Jan;74(1):6-10.

PMID:
15613100
9.

Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels.

Davis BH, Zarev PV.

Cytometry B Clin Cytom. 2005 Jan;63(1):16-22.

10.

Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.

Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.

Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1253-62. doi: 10.1161/ATVBAHA.110.203364. Epub 2010 Mar 18.

11.

Serum markers of macrophage activation in pre-eclampsia: no predictive value of soluble CD163 and neopterin.

Kronborg CS, Knudsen UB, Moestrup SK, Allen J, Vittinghus E, Møller HJ.

Acta Obstet Gynecol Scand. 2007;86(9):1041-6.

PMID:
17712642
12.

Soluble CD163 from activated macrophages predicts mortality in acute liver failure.

Møller HJ, Grønbaek H, Schiødt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM; U.S. Acute Liver Failure Study Group.

J Hepatol. 2007 Nov;47(5):671-6. Epub 2007 Jun 21.

13.

Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.

Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Jørgensen A, Hvid M, Deleuran B.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):689-92. Epub 2011 Sep 1.

PMID:
21813065
14.

Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease.

Møller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK.

Eur J Haematol. 2004 Feb;72(2):135-9.

PMID:
14962251
15.

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T.

J Clin Oncol. 2009 Jul 10;27(20):3330-7. doi: 10.1200/JCO.2008.19.9919. Epub 2009 Jun 15.

16.

Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.

Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S.

J Dermatol Sci. 2012 Oct;68(1):45-51. doi: 10.1016/j.jdermsci.2012.07.007. Epub 2012 Jul 27.

PMID:
22884782
17.

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis.

Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J.

Arthritis Rheum. 2009 Mar;60(3):883-91. doi: 10.1002/art.24349.

18.

New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis.

Gaïni S, Pedersen SS, Koldkaer OG, Pedersen C, Moestrup SK, Møller HJ.

Clin Exp Immunol. 2008 Mar;151(3):423-31. doi: 10.1111/j.1365-2249.2007.03586.x. Epub 2008 Jan 8.

19.

Serum neopterin and soluble CD163 as markers of macrophage activation in paracetamol (acetaminophen)-induced human acute liver injury.

Craig DG, Lee P, Pryde EA, Hayes PC, Simpson KJ.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1395-404. doi: 10.1111/apt.12530. Epub 2013 Oct 20.

PMID:
24138337
20.

Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.

Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M.

J Gastroenterol. 2005 Jan;40(1):52-6.

PMID:
15692789
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk